Literature DB >> 17306739

Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation.

Takaaki Koshiba1, Ying Li, Mami Takemura, Yanling Wu, Shimon Sakaguchi, Nagahiro Minato, Kathryn J Wood, Hironori Haga, Mikiko Ueda, Shinji Uemoto.   

Abstract

In the setting of our pediatric living-donor liver transplantation (LDLT), 87 patients (15.0% of all the patients: significantly higher proportion, compared with those of other transplant centers) achieved complete withdrawal of immunosuppression, which is referred to as "operational tolerance". Immunosuppressants were completely discontinued for 54 patients as scheduled, and for 33 because of EBV infection or other complications. Immunological analyses of the peripheral blood derived from operationally tolerant patients demonstrated that non-deletional tolerance takes place in which potentially reactive T cells to donor-antigens remain physically in the immune repertoire, but specifically suppressed by certain mechanisms. Not only CD4(+)CD25(high+) T cells were increased in the proportion in the tolerant patients' peripheral lymphocytes and suppressed MLR specifically to the donor antigen, but also FOXP3 expressing cells were present within the tolerant liver. Thus, among several mechanisms accounting for non-deletional tolerance, Tregs are likely to involve at least in part in our tolerant patients. Vdelta1gammadeltaT cells, a subset of gammadeltaT cells, which otherwise reside mainly in the intestine, emerge into the peripheral blood during successful pregnancy but not abortive pregnancy. Since Vdelta1gammadeltaT cells produce massive IL-10, it is proposed that Vdelta1gammadeltaT cells induce fetomaternal tolerance by promoting Th2 immune deviation. Consistent with pregnancy, IL-10 producing Vdelta1gammadeltaT cells emerge into the blood of our tolerant patients. This may reflect a common feature between fetomaternal tolerance and transplant tolerance. We began protocol biopsy in post-LDLT patients who exhibit normal liver function from January 2003. Operationally tolerant patients, albeit showing normal liver function, exhibited decrease in size and increase in number of the bile duct and the fibrosis to a greater extent, compared with patients on maintenance immunosuppression. This warrants serial protocol biopsy before and after complete cessation of immunosuppression even in the presence of normal liver function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17306739     DOI: 10.1016/j.trim.2006.10.004

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  41 in total

Review 1.  Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes.

Authors:  Carmen Fotino; Camillo Ricordi; Vincenzo Lauriola; Rodolfo Alejandro; Antonello Pileggi
Journal:  Rev Diabet Stud       Date:  2010-08-10

2.  Identification of a B cell signature associated with renal transplant tolerance in humans.

Authors:  Kenneth A Newell; Adam Asare; Allan D Kirk; Trang D Gisler; Kasia Bourcier; Manikkam Suthanthiran; William J Burlingham; William H Marks; Ignacio Sanz; Robert I Lechler; Maria P Hernandez-Fuentes; Laurence A Turka; Vicki L Seyfert-Margolis
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

3.  Aqueous extract of Caesalpinia sappan decelerates allograft rejection by inducing imbalance between CD4(+) CD25(+) T cells and Th17 cells.

Authors:  Chunxia Li; Hui Zhang; Dongqin Gao; Qun Ma; Zhihua Li; Jun Dai; Mingyan Zhang; Chuanping Si
Journal:  Int J Clin Exp Med       Date:  2015-05-15

4.  Marking a path to transplant tolerance.

Authors:  Vicki Seyfert-Margolis; Laurence A Turka
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

5.  Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively.

Authors:  Michael Ibrahim; Ismail El-Hamamsy; Mahmoud Barbir; Magdi H Yacoub
Journal:  J Cardiovasc Transl Res       Date:  2011-09-01       Impact factor: 4.132

6.  T regulatory cell mediated immunotherapy for solid organ transplantation: A clinical perspective.

Authors:  Mohammad Afzal Khan
Journal:  Mol Med       Date:  2016-11-22       Impact factor: 6.354

Review 7.  Histone deacetylase inhibitors and transplantation.

Authors:  Ran Tao; Edwin F de Zoeten; Engin Ozkaynak; Liqing Wang; Bin Li; Mark I Greene; Andrew D Wells; Wayne W Hancock
Journal:  Curr Opin Immunol       Date:  2007-08-24       Impact factor: 7.486

Review 8.  The SPLIT research agenda 2013.

Authors:  Estella M Alonso; Vicky L Ng; Ravinder Anand; Christopher D Anderson; Udeme D Ekong; Emily M Fredericks; Katryn N Furuya; Nitika A Gupta; Stacee M Lerret; Shikha Sundaram; Greg Tiao
Journal:  Pediatr Transplant       Date:  2013-05-30

9.  Expression of alpha smooth muscle actin in living donor liver transplant recipients.

Authors:  Masataka Hirabaru; Kyoko Mochizuki; Mitsuhisa Takatsuki; Akihiko Soyama; Taiichiro Kosaka; Tamotsu Kuroki; Isao Shimokawa; Susumu Eguchi
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

10.  T10B9 monoclonal antibody: a short-acting nonstimulating monoclonal antibody that spares gammadelta T-cells and treats and prevents cellular rejection.

Authors:  Thomas H Waid; John S Thompson; Maria Siemionow; Stephen A Brown
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.